“Shift Toward Targeted Neuroprotective and Anti-Inflammatory Therapies”
• A key trend in the global intracranial hematoma drug market is the focus on targeted therapies that address secondary brain injury mechanisms such as inflammation, oxidative stress, and neuronal apoptosis.
• There is a growing preference for neuroprotective agents, anticoagulant reversal drugs, and osmotic diuretics to manage acute hematoma symptoms and complications.
• For example, drugs like mannitol and hypertonic saline are widely used to reduce intracranial pressure and cerebral edema following hematoma.
• Novel delivery systems, including intranasal formulations and sustained-release injectables, are being developed to enhance brain penetration and rapid onset.
• The increasing incidence of traumatic brain injuries and advances in neuroimaging are driving demand for fast-acting pharmacologic interventions.
